-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The head of Takeda China's anti-tumor division is confirmed!
The head of Takeda China's anti-tumor division is confirmed!On the 26th, Takeda China announced to employees that Huang Haoyu formally joined Takeda China as the head of the anti-tumor division and became a member of Takeda China’s leadership team.
Before joining Takeda China, Huang Haoyu was the general manager of Baxter’s nephrology division in China.
Dami has introduced him before.
In June 2012, Huang Haoyu joined Roche as the Director of Oncology and Rheumatism Division in Taiwan.
On July 31, 2016, Huang Haoyu left Roche Pharmaceuticals and returned to his hometown to serve as AbbVie's general manager in Taiwan (see MRCLUB historical news: Roche Huang Haoyu resigned at the end of this month), dedicated to AbbVie’s development of the immune and tumor pipeline in Taiwan.
On June 15, 2018, Huang Haoyu returned to Shanghai and joined Baxter as the general manager of Baxter China's nephrology division (see MRCLUB historical news: Huang Haoyu will join Baxter China).
This time Huang Haoyu joined Takeda China, which attracted much attention from the industry.
According to my understanding at the time, Xu Jianen was suffering from eye disease.
As mentioned earlier, the anti-tumor field is one of Takeda’s global strategic priorities.
